Multisystem inflammatory syndrome-related refractory cardiogenic shock in adults after coronavirus disease 2019

David Tonon1, Clementine Landrieux1, Soline Van Den Plas1

  • 1Department of Cardiovascular Anaesthesiology and Critical Care Medicine, University Hospital Timone, 264 rue Saint Pierre, 13005 Cedex 5 Marseille, France.

Insights

Multisystem inflammatory syndrome in children (MIS-C) can affect young adults following COVID-19 infection, presenting as severe cardiogenic shock. Early treatment with immune globulin and steroids led to rapid recovery in two young adult cases.

Area of Science:

  • Pediatric Cardiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • A novel multisystem inflammatory syndrome in children (MIS-C) has been identified following COVID-19 infection.
  • MIS-C shares clinical features with Kawasaki disease, toxic shock syndrome, and macrophage activation syndrome, often involving cardiac complications.

Observation:

  • This case series describes two young adults without prior medical history who met MIS-C criteria.
  • Both patients presented with refractory cardiogenic shock, necessitating intensive care and mechanical circulatory support (venous-arterial extracorporeal membrane oxygenation).

Findings:

  • Early administration of intravenous immune globulin and high-dose corticosteroids resulted in complete recovery within two weeks for both patients.
  • MIS-C typically occurs 2-4 weeks post-SARS-CoV-2 infection and can lead to severe illness requiring intensive care.

Implications:

  • Early recognition and multidisciplinary management are crucial for improving outcomes in MIS-C patients, including young adults.
  • Understanding MIS-C pathogenesis, likely involving post-infectious immune dysregulation, is vital for broader COVID-19 research.
  • Prompt treatment with immune globulin and corticosteroids appears effective for MIS-C.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
94
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
41
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
31
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
60
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
25
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
41